3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 1
2
Phase EARLY_PHASE1
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
4
Breast
4
Sarcoma
3
Genitourinary
3
Thoracic
2
Dermatologic
2
CNS
2
Tumor-Agnostic
1
Other solid neoplasm
1
Other
1
Gynecologic
1
Conditions
Melanoma
2
Interventions
pembrolizumab
81
Nivolumab
55
Ipilimumab
44
Cyclophosphamide
38
aldesleukin
26
Interleukin-2
25
fludarabine
17
Temozolomide
17
fludarabine phosphate
16
trametinib
11
dabrafenib
11
Radiotherapy
11
Biopsy
11
avelumab
10
Paclitaxel
9
spartalizumab
8
cemiplimab
8
Dacarbazine
8
Cisplatin
8
Bevacizumab
8
sargramostim
7
binimetinib
7
Fluorouracil
7
poly ICLC
6
lenvatinib
6
epacadostat
6
atezolizumab
6
Magnetic Resonance Spectroscopy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Hydroxychloroquine
×
Dermatologic
×
Clear all
NCT04464759
2026-05-11
LIMIT
Abramson Cancer Center at Penn Medicine
Phase 1/2
Recruiting
94 enrolled
NCT03754179
2021-04-28
COMBI-R2
Universitair Ziekenhuis Brussel
Phase 1/2
Unknown
63 enrolled